NICE recommends MSD’s pembrolizumab to treat breast cancer
Nearly 1,600 people in England alone are expected to benefit from the immunotherapy drug. Previously, the drug was available for a small group of people with advanced TNBC
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.
The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release
The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces
The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)